---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-013169"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:36:19.104085+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports ~$158M cash; DMD gene editing abstract accepted at ASGCT

## Summary
- Expects ~$158M cash as of March 31, 2023; cash runway through Q1 2025.
- PBGENE-DMD preclinical data selected for oral presentation at ASGCT May 2023.
- ARCUS nucleases designed to excise ~500k bp mutation hot spot in dystrophin gene.
- Abstract available May 2, 2023 on ASGCT website.

## SEC filing metadata
- accession: 0000950170-23-013169
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/0000950170-23-013169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/dtil-20230418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-013169
- JSON: https://secwatch.observer/filing/0000950170-23-013169.json
- Plain text: https://secwatch.observer/filing/0000950170-23-013169.txt

## Key facts
- Earnings Releases
  PRECISION BIOSCIENCES INC reported preliminary financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: preliminary results
  source text: Although it has not finalized its full financial results for the quarter ended March 31, 2023, Precision BioSciences, Inc. (the “Company”) expects to report that it had approximately $158 million in cash and cash equivalents as of March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017023013169/0000950170-23-013169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.